跳转到主要内容
  • 关于 ELGA
    • 关于 ELGA
    • 超纯水
    • 纯化技术
    • 水中杂质
    • 白皮书
    • 认证合作伙伴
    • 可持续发展
    • 降低临床风险
    • 招贤纳士
    • 活动
    • HPLC 的制药应用
    • HPLC 水纯度
  • 博客
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment and sustainability
    • Life in the lab
    • Purelab product design
    • Science of the future
    • Water Purity
    • Water in the lab
  • 联系信息
  • English
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 日本語
首页 ELGA LabWater
  • 产品
  • 应用
  • 案例分析
  • 支持
  • 产品
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA 全产品系列
  • 应用
  • 案例分析
    • 雅培诊断的南亚团队选用 ELGA MEDICA 系统
    • 1+ 级超纯水对非专利药物开发的重要性
    • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
    • Clean Water for a Clean Future
    • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
    • DASA:巴西最大的医疗诊断公司
    • ELGA 帮助免疫血清学实验室最大程度地增加运行时间
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
    • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
    • PURELAB® flex:适合当今研究方法的理想培训系统
    • Powering Cutting-Edge Gene Research
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • 城市综合医院为西门子 ADVIA® 分析仪选配 MEDICA® Pro
    • ELGA LabWater and Beckman Coulter Join Forces
    • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
    • 借助超纯水,解开南极的秘密
    • Advancing Genetic Technologies
    • Cross Infection Control: Pure and Simple
    • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
  • 支持
    • 支持和服务
    • 实验室规划
    • 注册产品
    • Register Your Product (USA & Canada Only)
  • 产品
    • PURELAB
      • PURELAB® flex 1 & 2
      • PURELAB® flex 3 & 4
    • CENTRA
      • CENTRA® 60/120
      • CENTRA® RDS
      • CENTRA® R200
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® EDI 15/30
      • MEDICA® Pro EDI 60/120
      • MEDICA® Pro-LPS
      • MEDICA® Pro-R 和 Pro-RE
      • MEDICA® R200
    • BIOPURE
      • BIOPURE 7/15
      • BIOPURE 60/120
      • BIOPURE 200/300/600
    • ELGA 全产品系列
      • PURELAB® Classic
  • 应用
  • 案例分析
    • 雅培诊断的南亚团队选用 ELGA MEDICA 系统
    • 1+ 级超纯水对非专利药物开发的重要性
    • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
    • Clean Water for a Clean Future
    • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
    • DASA:巴西最大的医疗诊断公司
    • ELGA 帮助免疫血清学实验室最大程度地增加运行时间
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
    • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
    • PURELAB® flex:适合当今研究方法的理想培训系统
    • Powering Cutting-Edge Gene Research
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • 城市综合医院为西门子 ADVIA® 分析仪选配 MEDICA® Pro
    • ELGA LabWater and Beckman Coulter Join Forces
    • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
    • 借助超纯水,解开南极的秘密
    • Advancing Genetic Technologies
    • Cross Infection Control: Pure and Simple
    • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
  • 支持
    • 支持和服务
    • 实验室规划
    • 注册产品
    • Register Your Product (USA & Canada Only)
  • English
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 日本語
  • 隐私政策
  • 条款和条件
  • 全球法律合规
  • 专利
  • 页面操作员
  • 首页
  • Node
  • Exploring The Origins Of Childhood Leukaemia
Analytical Chemistry
Science of the Future

Exploring The Origins Of Childhood Leukaemia

29 3月 2020
- by Dr Alison Halliday

Child with Cancer

Researchers analyse archived newborn blood spots to look for exposures in the womb that may affect the risk of developing the most common childhood cancer.


Recent evidence suggests that childhood leukaemia involves at least two events – the first occurring when the baby is developing in the womb, with a second following after their birth. Although the precise factors that contribute to these events are not fully understood, the rising incidence of childhood leukaemia over time, particularly in affluent countries, suggests that environmental and lifestyle factors are involved.

Both the developing fetus and child are exposed to a multitude of potentially harmful chemicals – such as those generated from intrinsic metabolic processes or from exogenous sources including infections, diet or parental smoking.

Although many of these chemicals are stable molecules that can be measured with techniques such as metabolomics or proteomics, others are metabolised into electrophilic compounds that can alter physiological processes in early life but can’t be measured in the body. This makes it challenging for researchers to investigate their potential impact on the risk of developing a disease later in life.

A Proxy Marker In Newborn Blood Spots

The Cys34 residue of the most abundant blood protein, human serum albumin (HSA), is a powerful scavenger of electrophilic compounds. As its turnover in the body is 28 days, measuring the modifications (adducts) of this amino acid in archived newborn blood spots offers an indirect way to capture fetal exposures during the last month of pregnancy. 

In a new study, published in Leukemia Research, a team of researchers analysed these Cys34 adducts in the HSA protein in archived newborn blood spots as a way obtain new information about exposures in the womb and investigate how these may impact on the risk of childhood leukaemia.1 

The team used an adapted untargeted adductomics method based on nanoflow liquid chromatography-high resolution mass spectrometry (nLC-HRMS) to characterise Cys34 adducts in the archived newborn blood spots. They used ultrapure water from an ELGA PURELAB® laboratory water purification system to minimise the risk of introducing contaminants that may affect the results of this sensitive analytical technique.

Comparing Abundances In Cases And Controls

The researchers analysed 782 archived newborn blood spots collected from participants of the California Childhood Leukaemia Study (CCLS) – including 338 children with acute lymphoblastic leukaemia (ALL), 45 with acute myeloid leukaemia (AML) and matched healthy controls.

While they identified no clear associations between adduct abundance with either childhood leukaemia or ALL overall, they did identify differences between samples from children with subtypes of the disease and healthy controls – albeit in small sample sizes.

Children with T-cell ALL had higher abundances of adducts of reactive carbonyl species. And interestingly, there was a 44% decrease in abundances of a homocysteine adduct in AML cases.

Preventing Childhood Leukaemia

Although the results shed light on potential exposures involved in the development of certain subtypes of ALL before birth, larger studies are now needed to confirm these findings and further explore their implications.

As there are very few known lifestyle-related or environmental causes of childhood leukaemias, identifying modifiable risk factors could lead to new ways to help reduce the risk of the disease.

Why Choose ELGA LabWater?

ELGA LabWater has been a trusted name in pure and ultrapure water since 1937. Our dedication to ultrapure and pure water is a guarantee that we will continue to provide the best solutions with the best service.


Reference:

  1. Yano, Y. et al. Untargeted Adductomics of Newborn Dried Blood Spots Identifies Modifications to Human Serum Albumin Associated with Childhood Leukaemia. Leukemia Research 2019; S0145-2126(19)30713-1.


Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

Quest Download

PURELAB Quest

The only purifier on the market that dispenses all 3 types of science ready water from a compact, economical and easy to use system!

             Click Here To Find Out More

 

  • Enquiry
  • 获取报价
  • 预订演示
  • 联系获认证的合作伙伴

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

获取报价

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

预订演示

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

Elga LabWater 总部

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
电话: +44 (0) 203 567 7300
传真:+44 (0) 203 567 7205

超纯水专家

  • 支持和服务
  • 活动

案例研究

  • 雅培诊断
  • DASA 医学诊断
  • NeoDIN 医学研究所
  • 北斯塔福德郡 NHS 信托大学医院
  • Olsberg 职业技术学院

资源

  • 了解超纯水
  • 白皮书
  • 水纯化技术
  • 实验室应用
  • 水中杂质

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • 语言
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Veolia 其他站点
    • Veolia
    • Veolia Fondation
    • Veolia Water Technologies

© VWS (UK) Ltd. 以 ELGA®LabWater 的名义经营业务。2021- 保留所有权利
ELGA 是 Veolia 旗下全球实验室用水品牌。

  • 隐私政策
  • 条款和条件
  • 全球法律合规
  • 专利
  • 页面操作员
Elga Veolia
TOP

© 2017 ELGA Veolia